Botanix Pharmaceuticals Limited (BXPHF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $49.2M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBotanix Pharmaceuticals Limited (BXPHF) trades at $0.018. Botanix Pharmaceuticals Limited is an Australian company focused on the research and development of dermatology and antimicrobial products. Market cap: $49.2M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BXPHF: BXPHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BXPHF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
BXPHF: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Botanix Pharmaceuticals Limited (BXPHF) Healthcare & Pipeline Overview
Botanix Pharmaceuticals Limited, based in Australia, specializes in developing novel dermatology and antimicrobial treatments, with a pipeline including Phase 3-ready Sofpironium Bromide for hyperhidrosis and other candidates targeting acne, rosacea, and bacterial infections, positioning them in the competitive biotechnology sector.
What Is the Investment Thesis for BXPHF?
Botanix Pharmaceuticals presents a focused investment opportunity within the dermatology and antimicrobial space. The company's lead product candidate, Sofpironium Bromide, which has completed Phase 3 trials for hyperhidrosis, represents a near-term value driver, contingent on regulatory approval and subsequent commercialization. Further value lies in the advancement of other pipeline assets, including BTX 1503 for acne and BTX 1702 for rosacea, both in Phase IIb trials. However, the company's negative profit margin of -404.7% and gross margin of -118.2% highlight the risks associated with biotechnology companies that are pre-revenue or heavily investing in R&D. Successful navigation of regulatory pathways and strategic partnerships will be crucial for realizing the potential value of Botanix's pipeline. The company's market capitalization is approximately $0.09 billion as of 2026-03-17.
Based on FMP financials and quantitative analysis
BXPHF Key Highlights
Sofpironium Bromide has completed Phase 3 clinical programs for the treatment of primary axillary hyperhidrosis.
- BTX 1503, a transdermal gel formulation for acne, has completed Phase II clinical trials.
- BTX 1801 has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus.
- BTX 1702 is in Phase IIb clinical trials for the treatment of papulopustular rosacea.
- The company's market capitalization is $49.2M as of 2026-03-17.
Who Are BXPHF's Competitors?
BXPHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AAWH Ascend Wellness Holdings, Inc. | $0.49 | +1.36% | $98.7M | 439-signal |
| BRIBF Brii Biosciences Limited | $0.13 | 0.00% | $93.8M | — |
| HOFBF Hofseth BioCare ASA | $0.17 | 0.00% | $68.5M | 439-signal |
| IPHYF Innate Pharma S.A. | $1.65 | 0.00% | $155M | — |
| JWCTF JW (Cayman) Therapeutics Co. Ltd | $0.20 | 0.00% | $84.2M | 549-signal |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BXPHF's Key Strengths?
Pipeline of dermatology and antimicrobial products.
- Sofpironium Bromide has completed Phase 3 trials.
- Experienced management team.
- Focus on unmet medical needs.
What Are BXPHF's Weaknesses?
Negative profit margin.
- Reliance on successful clinical trial outcomes.
- Limited commercialization experience.
- Dependence on regulatory approvals.
What Could Drive BXPHF Stock Higher?
Potential regulatory approval of Sofpironium Bromide for hyperhidrosis.
- Results from ongoing clinical trials for BTX 1503, BTX 1702, and BTX 1801.
- Advancement of the product pipeline through clinical development stages.
- Strategic partnerships for commercialization and distribution.
- Expansion of the product pipeline to include treatments for other dermatological conditions.
What Are the Key Risks for BXPHF?
Financial-distress signal — its Altman Z-Score of -6.10 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trial outcomes for drug candidates.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from other pharmaceutical companies.
- Dependence on successful commercialization of approved products.
- Negative profit margin and reliance on funding for R&D.
What Are the Growth Opportunities for BXPHF?
- Growth opportunity 1: Successful commercialization of Sofpironium Bromide for hyperhidrosis represents a significant growth opportunity. The global hyperhidrosis treatment market is expected to reach $1.5 billion by 2030. Upon regulatory approval, Botanix can capture a share of this market through effective marketing and distribution strategies. The timeline for this growth is dependent on regulatory approval, which is anticipated within the next 12-18 months.
- Growth opportunity 2: Expansion of the acne treatment pipeline with BTX 1503 offers another avenue for growth. The global acne treatment market is projected to reach $13.2 billion by 2033. Positive Phase III trial results and subsequent regulatory approval could position BTX 1503 as a competitive product in this market. This growth is anticipated within the next 2-3 years, contingent on successful trial outcomes.
- Growth opportunity 3: Development of BTX 1702 for rosacea provides an opportunity to address a growing market segment. The global rosacea treatment market is expected to reach $2.6 billion by 2033. Successful completion of Phase IIb trials and subsequent advancement through the regulatory process could lead to commercialization within the next 3-4 years.
- Growth opportunity 4: Exploring strategic partnerships for commercialization and distribution can accelerate market penetration. Collaborating with established pharmaceutical companies can provide access to existing distribution networks and marketing expertise, reducing the time and cost associated with launching new products. These partnerships could be established within the next 12 months.
- Growth opportunity 5: Expanding the pipeline to include treatments for other dermatological conditions can diversify the company's revenue streams and reduce reliance on individual products. Identifying and developing new drug candidates for conditions with unmet medical needs can create long-term growth opportunities. This expansion could begin within the next 2 years, focusing on areas with high market potential.
What Are BXPHF's Competitive Advantages?
- Proprietary drug formulations.
- Patent protection for novel treatments.
- Clinical trial data supporting efficacy and safety.
- Expertise in dermatology and antimicrobial drug development.
What Does BXPHF Do?
Botanix Pharmaceuticals Limited, incorporated in 1984 and headquartered in Leederville, Australia, is a biotechnology company dedicated to the research and development of innovative dermatology and antimicrobial solutions. The company focuses on addressing common skin diseases and infections through the development of novel treatments. Botanix's product pipeline features several promising candidates, including Sofpironium Bromide, a drug for primary axillary hyperhidrosis that has completed Phase 3 clinical programs. Additionally, BTX 1503, a transdermal gel formulation, is in development for the treatment of serious acne in adults and teenagers, having completed Phase II clinical trials. BTX 1801 has completed Phase IIb clinical trials for treating staphylococcus aureus and methicillin-resistant staphylococcus aureus. BTX 1702 is in Phase IIb clinical trials for papulopustular rosacea, and BTX 1204A is being developed for atopic dermatitis. Botanix Pharmaceuticals aims to provide effective and safe treatments for a range of dermatological conditions and infections, addressing unmet needs in the market. Their focus on late-stage clinical programs positions them for potential commercialization in the near future, pending regulatory approvals.
What Products and Services Does BXPHF Offer?
- Researches and develops dermatology products.
- Develops antimicrobial products.
- Creates novel treatments for common skin diseases.
- Develops treatments for skin infections.
- Conducts clinical trials for drug candidates.
- Seeks regulatory approvals for new products.
How Does BXPHF Make Money?
- Develops pharmaceutical products for dermatology and antimicrobial applications.
- Out-licenses or commercializes approved products.
- Generates revenue through product sales and partnerships.
What Industry Does BXPHF Operate In?
Botanix Pharmaceuticals operates within the biotechnology sector, specifically targeting dermatology and antimicrobial markets. The global dermatology market is characterized by increasing demand for treatments addressing skin diseases and infections. Competition includes companies developing similar products, with the success of Botanix contingent on clinical trial outcomes, regulatory approvals, and market adoption. The company's focus on specific dermatological conditions like hyperhidrosis, acne, and rosacea allows it to target niche markets within the broader dermatology landscape. The biotechnology industry is characterized by high R&D costs and regulatory hurdles, making strategic partnerships and efficient clinical trial management crucial for success.
Who Are BXPHF's Key Customers?
- Patients with skin diseases and infections.
- Dermatologists and other healthcare professionals.
- Pharmaceutical companies through partnerships and licensing agreements.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● Reported in AUD, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 52 |
| 2026-08-26 | 52 |
| 2026-08-29 | 52 |
| 2026-09-01 | 52 |
| 2026-09-04 | 52 |
| 2026-09-07 | 52 |
| 2026-09-10 | 52 |
What changed?
The score has stayed at 52.
Over the same 18 days the stock moved +7.1%.
Forward Outlook
Wall Street analysts project Botanix Pharmaceuticals Limited revenue of about $33.3M for fiscal 2026, with EPS near $-0.03.
Earnings Track Record
Botanix Pharmaceuticals Limited has missed Wall Street's EPS estimate in 3 of its last 4 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 515.3% below estimates on average.
Financial Health
Botanix Pharmaceuticals Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.10 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -90.0%, showing how much profit it generates from its asset base. A current ratio of 2.56 indicates the company holds enough short-term assets to cover its near-term obligations.
Botanix Pharmaceuticals Limited (BXPHF) Valuation Context
Valued at $49.2M, BXPHF is classified as a micro-cap stock.
BXPHF Revenue & Earnings Trend
In Jun 2026, BXPHF generated $12.9M in top-line revenue, marking a sequential increase of 9.0%. The company recorded a net loss of $26.2M, with diluted EPS of $-0.01. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, BXPHF averaged $-0.01 in diluted EPS.
Company Profile
Botanix Pharmaceuticals Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Melbourne, AU. The company is led by CEO Howie McKibbon. BXPHF has traded publicly since 2019.
BXPHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Pipeline of dermatology and antimicrobial products.
- Sofpironium Bromide has completed Phase 3 trials.
- Experienced management team.
- Focus on unmet medical needs.
Bear Case
- Negative profit margin.
- Reliance on successful clinical trial outcomes.
- Limited commercialization experience.
- Dependence on regulatory approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Jun 2026 | $13M | -$26M | -$0.01 |
| Dec 2025 | $12M | -$24M | -$0.01 |
| Jun 2025 | $4M | -$40M | -$0.02 |
| Dec 2024 | $270,872.984 | -$22M | -$0.01 |
Based on FMP financials and quantitative analysis · Converted to USD from AUD at today's rate
BXPHF Latest News
BXPHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BXPHF.
Price Targets
Wall Street price target analysis for BXPHF.
BXPHF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BXPHF; grades run from A+ (80-100) to F (below 30).
Leadership: Howie McKibbon
CEO
Howie McKibbon serves as the CEO of Botanix Pharmaceuticals Limited. His leadership is focused on guiding the company through its clinical development programs and towards potential commercialization of its dermatology and antimicrobial products.
Track Record: Under Howie McKibbon's leadership, Botanix Pharmaceuticals has advanced its pipeline of dermatology and antimicrobial products, including the completion of Phase 3 clinical trials for Sofpironium Bromide. Further details regarding specific achievements and strategic decisions under his leadership are not available in the provided data.
BXPHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Botanix Pharmaceuticals may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and requires careful due diligence by investors.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Lower liquidity compared to major exchanges.
- Potential for price volatility.
- Higher risk of fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements.
- Research the management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's regulatory filings and disclosures.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any legal or regulatory issues.
- Completion of Phase 3 clinical trials for Sofpironium Bromide.
- Development of multiple drug candidates in the pipeline.
- Focus on addressing unmet medical needs.
- Experienced management team.
- Patent protection for novel treatments.
Common Questions About BXPHF (Healthcare)
Is BXPHF a good stock?
Stock Expert AI does not rate BXPHF buy, sell or hold. Botanix Pharmaceuticals Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Botanix Pharmaceuticals Limited do?
Botanix Pharmaceuticals Limited is an Australian biotechnology company focused on the research and development of dermatology and antimicrobial products. They are developing novel treatments for common skin diseases and infections, with a pipeline including Sofpironium Bromide for hyperhidrosis, BTX 1503 for acne, BTX 1702 for rosacea, and BTX 1801 for staphylococcus aureus infections.
What are the key factors to evaluate for BXPHF?
Evaluate BXPHF on fundamentals, analyst consensus, and risk factors. Further value lies in the advancement of other pipeline assets, including BTX 1503 for acne and BTX 1702 for rosacea, both in Phase IIb trials. Not financial advice.
How frequently does BXPHF data refresh on this page?
BXPHF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BXPHF's recent stock price performance?
Botanix Pharmaceuticals Limited (BXPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Pipeline of dermatology and antimicrobial products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BXPHF overvalued or undervalued right now?
Botanix Pharmaceuticals Limited (BXPHF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BXPHF?
Yes, most major brokerages offer fractional shares of Botanix Pharmaceuticals Limited (BXPHF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BXPHF's earnings and financial reports?
Botanix Pharmaceuticals Limited (BXPHF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BXPHF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.